Recombinant factor VIIa in the management of a pseudotumour in acquired haemophilia

Haemophilia

Volumn 3, Issue 1, 1997, Pages 54-58

  Maliekel, K ^a   Rana, N ^a   Green, D ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Acquired haemophilia; Pseudotumour; Recombinant VIIa

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; CYCLOPHOSPHAMIDE; PREDNISONE; VINCRISTINE;

ADULT; ANAPHYLAXIS; ANTIBODY TITER; ARTICLE; CASE REPORT; FEMALE; FOLLOW UP; GLUTEUS MAXIMUS MUSCLE; HEMOPHILIA; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; PSEUDOTUMOR;

EID: 0031029904     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1997.00075.x     Document Type: Article

References (15)

1. Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia: a natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147: 1077-81.
2. Kessler CM. An introduction to factor VIII inhibitors: the detection and quantitation. Am J Med 1991; 91 (suppl. 5A): 1S-5S.
3. Lian EC-Y, Larcada AF, Chiu AY-Z. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med 1989; 110: 774-8.
4. Green D. Spontaneous inhibitors of factor VIII. Br J Haematol 15: 57-75.
5. Biggs R, Austen DEG, Denson KWE, Rizza CR, Borrett R. The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs. Br J Haematol 1972; 23: 125-36.
6. Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 1982; 60: 1103-9.
7. Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993; 81: 1513-20.
8. Kurcznski E, Penner JA. Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med 1974; 291: 164-7.
9. Knobl P, Derfler K, Korniger L, et al. Elimination of acquired factor VIII antibodies by extracorporal antibody-based immunoadsorption (Ig-Therasorb). Thromb Haemostas 1995; 74: 1035-8.
10. Kasper CK. Treatment of factor VIII inhibitors. Prog Hemostas Thromb 1989; 9: 57-86.
11. Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1991; 28 (suppl. 6): 3-5.
12. Rapaport SI. Inhibition of factor VIIa/tissue factor-induced blood coagulation, with particular emphasis upon a factor Xa-dependent inhibitory mechanism. Blood 1989; 73: 359-65.
13. O'Marcaigh AS, Schmalz BJ, Shaughnessy WJ, Gilchrist GS. Successful hemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with severe hemophilia A and a potent inhibitor. Mayo Clin Proc 1994; 69: 641-4.
14. Schulman S, Lindstedt M, Alberts KA, Agren P-H. Recombinant factor Vila in multiple surgery. Thromb Haemostas 1994; 71: 154-61.
15. Glazer S, Hedner U, Falch JF. Pathologic inhibitors: management with factor VIIa. In: Green D, ed. Anticoagulants - Physiologic, Pathologic, Pharmacologic. Boca Raton: CRC Press, 1994; 131-41.